-
NASDAQ Stocks Hitting 52-Week Lows
Tuesday, June 21, 2011 - 10:24am | 129Westwood One Inc (NASDAQ: WWON) shares fell 2.83% to create a new 52-week low of $4.80. WWON's trailing-twelve-month ROE is -1,042.55%. Vimicro International Corporation (NASDAQ: VIMC) shares dropped 3.55% to create a new 52-week low of $1.90. VIMC reported the promotions of Mr. Yundong Zhang to...
-
Morning Market Losers
Tuesday, June 21, 2011 - 9:58am | 113Cleantech Solutions International Inc (NASDAQ: CLNT) dipped 12.50% to $1.26 at 9:55 am. Cleantech Solutions International Inc (formerly known as China Wind Systems Inc) (NASDAQ: CWS) changed its corporate name to Cleantech Solutions International Inc on June 13, 2011. Nanosphere Inc (NASDAQ: NSPH...
-
CEL-SCI Corporation Announces Data Showing Cancer Drug Multikine Lowers Cholesterol in Clinical Studies
Tuesday, June 21, 2011 - 9:05am | 227CEL-SCI Corporation (NYSE: CVM) announced today data from its Phase II clinical studies which showed that its lead drug Multikine was able to lower cholesterol in studies involving 120 head and neck cancer patients. The studies were primarily designed to determine the safety and efficacy of the...
-
DARA BioSciences to Present Positive Results of DB959 Phase I Study at the Upcoming 71st ADA Scientific Sessions
Tuesday, June 21, 2011 - 8:45am | 138DARA BioSciences, Inc. (Nasdaq: DARA) announced that an abstract has been accepted for presentation at the annual American Diabetes Association Scientific Sessions to be held in San Diego, CA, June 24 - 28, 2011. The presentation will provide details on the company's lead once-a-day, oral diabetes...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Tuesday, June 21, 2011 - 8:17am | 129Tower Bancorp Inc (NASDAQ: TOBC) shares advanced 35.49% to $27.60 in the pre-market session. Susquehanna Bancshares Inc agreed to acquire Tower Bancorp for $343 million in cash and stock, representing a 41% premium over Tower's closing stock price on Friday. Biogen Idec Inc (NASDAQ: BIIB) shares...
-
AVI BioPharma Expands Clinical Pipeline With Initiation of Phase 1 Study of Influenza Therapeutic Candidate
Tuesday, June 21, 2011 - 8:12am | 78AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it initiated dosing of volunteers in a Phase 1 clinical study of AVI-7100, the Company's lead drug candidate for the treatment of influenza. AVI-7100 is a therapeutic candidate with a novel mechanism of action and potentially broad-spectrum...
-
Hemispherx Biopharma's Ampligen Tested in Combination With Experimental Vaccine From Leading Cancer Research Institute
Tuesday, June 21, 2011 - 8:11am | 141Hemispherx Biopharma (NYSE: HEB) today announced that it has entered into a Material Transfer and Research Agreement with the University of Pennsylvania School of Medicine to provide Ampligen® [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic, for testing as a vaccine adjuvant in a...
-
News Summary for June 21, 2011
Tuesday, June 21, 2011 - 8:06am | 355This is your Benzinga news summary and traders' outlook for Tuesday, June 21, 2011, covering headlines from overnight and Tuesday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are trading higher as the U.S. dollar is slightly lower this morning on optimism of a...
-
Benzinga's Top Upgrades
Tuesday, June 21, 2011 - 8:03am | 136Davenport upgraded Universal Stainless & Alloy Products Inc (NASDAQ: USAP) from “neutral” to “buy.” USAP's shares closed at $40.65 yesterday. USAP's trailing-twelve-month operating margin is 11.71%. Analysts at Deutsche Bank upgraded Biogen Idec Inc (NASDAQ: BIIB) from “hold” to “buy.” BIIB's...
-
OPKO Health Repurchases Approximately 2.4 Million Shares
Tuesday, June 21, 2011 - 8:00am | 49OPKO Health, Inc. (NYSE: OPK) today announced that the Company repurchased approximately 2.4 million shares of its common stock for approximately $7.8 million, including commissions, from an early investor in Acuity Pharmaceuticals, the Company's predecessor. The repurchase was funded with cash on...
-
UPDATE: Deutsche Bank Upgrades Biogen Idec to Buy
Tuesday, June 21, 2011 - 7:51am | 138Deutsche Bank is out with its report today on Biogen Idec (NASDAQ: BIIB), upgrading BIIB from Hold to Buy. In a note to clients, Deutsche Bank writes, "We view Biogen Idec as the large cap biotech stock with the greatest opportunity for upside: 1) Our analysis suggests CONFIRM will show BG-12 is...
-
Wedbush Maintains Outperform on Chelsea Therapeutics
Tuesday, June 21, 2011 - 7:41am | 107Wedbush is out with its report today on Chelsea Therapeutics (NASDAQ: CHTP), maintaining Outperform. In a note to clients, Wedbush writes, "We maintain our OUTPERFORM rating and fair value of $8. We believe the recent rise in CHTP resulted from the impact of data presented at ICPDMD and...
-
Cytokinetics Announces Opening of Next Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
Tuesday, June 21, 2011 - 7:35am | 93Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened enrollment in a second Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis. CK-2017357, a fast skeletal muscle troponin activator, selectively activates the fast skeletal muscle...
-
Palatin Technologies Issued U.S. Patent for Key Component in PL-3994 Drug Candidate
Tuesday, June 21, 2011 - 7:34am | 104Palatin Technologies, Inc. (NYSE: PTN) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs." The claims in the issued patent cover a series of small molecule mimics for naturally occurring amino acids...
-
Gentium Signs License and Distribution Agreement for Defibrotide With Medison Pharma Ltd. in Israel and the Palestinian Authority
Tuesday, June 21, 2011 - 7:32am | 210Gentium S.p.A. (Nasdaq: GENT) announced that the Company has signed a ten-year exclusive license and distribution agreement with Medison Pharma Ltd. for defibrotide in Israel and the Palestinian Authority. Under the terms of the agreement, Medison will be responsible for managing the named-patient...